Table 2.

Population prevalence of HPV 16, 18, 31, 33, 45 and relative risk with 95% confidence intervals for A) squamous cancer (SCC), B) Adenocarcinoma (ADC, including adenosquamous cancer) and C) adenocarcinoma in situ (AIS).

A. Squamous cancer
Study	HPV type	Population prevalence % (95% CI)	Prevalence in squamous cancer % (95% CI)	Rel risk for squamous cancer (95% CI)	Rank
IARC (world) [[21], [22], Table 2; Table 2] N=15, 613 normal, 9494 SCC	16	1.8 (1.6, 2.0)	55.2 (54.2, 56.2)	30.6 (27.2, 34.4)	1
	18	.66 (0.54, 0.80)	12.8 (12.1, 13.5)	19.4 (15.9, 23.7)	2
	31	.69 (0.56, 0.83)	3.8 (3.4, 4.2)	5.5 (4.4, 6.9)	5
	33	.53 (0.42, 0.66)	3.7 (3.3, 4.1)	7.0 (5.5, 8.9)	4
	45	.51 (0.41, 0.64)	4.6 (4.1, 5.2)	9.0 (7.0, 11.5)	3

New Mexico [[16], Table 2 and new data for SCC only^a] N=4007 controls, 660 SCC	16	7.4 (6.6, 8.3)	58.0 (54.2, 61.8)	7.8 (6.9, 8.9)	1
	18	2.3 (1.8, 2.8)	9.8 (7.7, 12.4)	4.3 (3.2, 5.9)	3
	31	2.9 (2.4, 3.5)	4.2 (2.8, 6.1)	1.4 (.97, 2.3)	6
	33	.92 (0.65, 1.3)	4.8 (3.3, 6.8)	5.2 (3.3, 8.4)	2
	45	2.2 (1.8, 2.8)	6.5 (4.6, 8.7)	2.9 (2.0, 4.1)	4
					HPV35 5th

Denmark [[20], Tables 1 and 2] (N=40 382, 19 SCC)	16	5.4 (5.1, 5.9)	57.9 (33.5, 79.7)	10.8 (7.3, 15.9)	1
	18	2.4 (2.2, 2.5)	10.5 (13.0, 33.1)	4.4 (1.2, 16.4)	4
	31	3.8 (3.6, 4.0)	5.3 (1.3, 26.0)	1.4 (0.21, 9.4)	5
	33	1.7 (1.6, 1.9)	10.5 (13.0, 33.1)	6.1 (1.63, 22.5)	3
	45	1.9 (1.8, 2.1)	15.8 (3.38, 39.6)	6.7 (2.3, 19.3)	2

B. Adenocarcinoma (including adenosquamous)
Study	HPV type	Population prevalence % (95% CI)	Prevalence in adenocarcinoma % (95% CI)	Rel risk for adenocarcinoma (95% CI)	Rank
IARC (world) [[23], Table 2] N=157 cases, 1609 controls	16	4.7 (3.7, 5.9)	42.7 (34.8, 50.8)	9.0 (6.8, 12.0)	3
	18	1.2 (.71, 1.8)	31.8 (24.6, 39.7)	27.0 (16.3, 44.6)	1
	31	0 (0.0, .2)	0 (0, 2.3)	–	–
	33	.06 (.02, .35)	.6 (.01, .35)	10.2 (.64, 163)	2
	45	.68 (.34, 1.2)	3.8 (1.4, 8.1)	5.6 (2.1, 15.1)	4

New Mexico [[16], Table 2 and new data for ADC only^a] N=122 ADC, 4007 controls	16	7.4 (6.6, 8.3)	36.9 (28.3, 46.1)	5.0 (3.9, 6.4)	2
	18	2.3 (1.8, 2.8)	28.9 (20.9, 37.6)	12.6 (8.9, 17.8)	1
	31	2.9 ((2.4, 3.5)	3.3 (0.90, 8.2)	1.1 (.42, 3.0)	4
	33	.92 (0.65, 1.3)	0 (0, 3.0)	0	–
	45	2.2 (1.8, 2.8)	.8 (.02, 4.5)	1.5 (.55, 3.9)	3

Denmark [[20], Tables 1 and 2] (N =40 382, 8 ADC)	16	5.4 (5.1, 5.9)	0 (0, 36.9)	0	–
	18	2.4 (2.2, 2.5)	87.5 (47.3, 99.7)	36.8 (28.1, 48.1)	1
	31	3.8 (3.6, 4.0)	12.5 (.32, 52.7)	3.3 (.53, 21.8)	2
	33	1.7 (1.6, 1.9)	0 (0, 36.9)	0	–
	45	1.9 (1.8, 2.1)	0 (0, 36.9)	0	–

C. Adenocarcinoma in Situ (AIS)
Study	HPV type	Population prevalence % (95% CI)	Prevalence in AIS % (95% CI)	Rel Risk for AIS (95% CI)	Rank
New Mexico [[16], Table 2 and new data^a for AIS only] N=4007 controls, 25 AIS	16	7.4 (6.6, 8.3)	48.0 (27.8, 68.0)	6.5 (4.2, 9.9)	2
	18	2.3 (1.8, 2.8)	48.0 (27.8, 68.0)	21.1 (13.4, 33.3)	1
	31	2.9 (2.4, 3.5)	0 (0, 13.7)	0	–
	33	.92 (.65, 1.3)	0 (0, 13.7)	0	–
	45	2.2 (1.8, 2.8)	4.0 (0.10, 20.4)	1.8 (.26, 12.3)	3

Controls in Vaccine trials 15–26y [[18], Tables 1 and 3] N=17 590, 19 AIS	16	8.8 (8.4, 9.3)	78.9 (54.4, 93.9)	8.9 (7.1, 11.3)	2
	18	3.6 (3.4, 3.9)	36.8 (16.3, 61.6)	10.7 (5.9, 19.1)	1
	31	4.4 (4.1, 4.8)	0 (0, 17.6)	0	–
	33	2.0 (1.8, 2.2)	5.3 (.13, 26.0)	2.5 (.38, 17.5)	3
	45	2.4 (2.2, 2.6)	5.3 (.13, 26.0)	1.9 (0.29, 13.3)	4

Denmark [[20], Tables 1 and 2] (N=40 382, 23 AIS)	16	5.4 (5.1, 5.9)	43.5 (23.2, 65.5)	8.1 (5.1, 12.9)	4
	18	2.4 (2.2, 2.5)	60.9 (38.5, 80.3)	25.6 (18.3, 35.7)	1
	31	3.8 (3.6, 4.0)	30.4 (13.2, 52.9)	8.1 (4.4, 15.0)	5
	33	1.7 (1.6, 1.9)	21.7 (7.5, 43.7)	12.5 (5.7, 27.2)	2
	45	1.9 (1.8, 2.1)	17.4 (5.0, 38.8)	8.9 (3.7, 21.9)	3

See Supplementary Tables for detailed breakdown of disease categories.